

Renalytix plc
("Renalytix" or the "Company")

Publication of Annual Report 2024 and Notice of 2024 Annual General Meeting

LONDON and NEW YORK, 26 November 2024Renalytix plc (LSE: REXX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that the Annual Report for the year ended 30 June 2024 and the Notice of 2024 Annual General Meeting ("AGM") have now been published on the Company's website (<https://investors.renalytix.com/financials-and-filings/annual-and-half-year-reports> and <https://investors.renalytix.com/news-and-events/documents-and-presentations>), and posted to shareholders who have not consented to receive electronic communications.

The AGM will be held in-person on 19 December 2024 at 11.00 (GMT) at 6 Stratton Street Mayfair, London W1J 8LD.

To help with practical arrangements for the AGM, any shareholder wishing to attend is requested to register first by contacting Walbrook PR via email at renalytix@walbrookpr.com or by telephone at +44 (0)20 7933 8780.

For further information, please contact:

Renalytix plc
James McCullough, CEO

www.renalytix.com
Via Walbrook PR

Stifel (Nominated Adviser, Joint Broker)
Nicholas Moore / Nick Harland / Ben Good

Tel: 020 7710 7600

Oberon Capital (Joint Broker)
Mike Seabrook / Nick Lovering

Tel: 020 3179 5300

Walbrook PR Limited
Paul McManus / Alice Woodings

Tel: 020 7933 8780 or renalytix@walbrookpr.com
Mob: 07980 541 893 / 07407 804 654

CapComm Partners
Peter DeNardo

Tel: 415-389-6400 or investors@renalytix.com

About Renalytix

Renalytix (LSE: REXX) (OTCQB: RNLXY) is an artificial intelligence enabled in-vitro diagnostics and laboratory services company that is the global founder and leader in the field of bioprognosis™ for kidney health. In late 2023, our kidneyintelX.dkd test was recognized as the first and only FDA-authorized prognostic test to enable early-stage CKD (stages 1-3b) risk assessment for progressive decline in kidney function in T2D patients. By understanding how disease will progress, patients and clinicians can take action earlier to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NOAEANFSAEXLFFA